Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 115Myelodysplastic Syndromes 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Leukemia 74Hodgkin Disease 73Leukemia, Lymphocytic, Chronic, B-Cell 72Multiple Myeloma 71Lymphoma, Non-Hodgkin 71Lymphoma 66Myeloproliferative Disorders 54Graft vs Host Disease 50Lymphoma, Follicular 49Lymphoma, Mantle-Cell 47Leukemia, Myeloid, Accelerated Phase 47Lymphoma, Large B-Cell, Diffuse 46Congenital Abnormalities 46Leukemia, Myelomonocytic, Chronic 44Lymphoma, B-Cell, Marginal Zone 43Hematologic Neoplasms 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 42Leukemia, Myeloid, Chronic-Phase 41Burkitt Lymphoma 40Primary Myelofibrosis 39Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 32Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 24Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 24Lymphoma, T-Cell, Cutaneous 23

Interventions

Cyclophosphamide 3thymoglobulin 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × beta-Thalassemia × Tacrolimus × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡